Sintilimab plus capecitabine after chemoradiation for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding an extra treatment after standard chemoradiation can reduce the chance of nasopharyngeal cancer coming back. The new treatment combines an immunotherapy drug (sintilimab) with a chemotherapy pill (capecitabine) for a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with nasopharyngeal cancer (a type of cancer in the back of the nose and throat).
- Your cancer is at high risk of coming back after standard treatment, based on its stage.
- You have already completed standard treatment (chemotherapy and radiation) and are within 2 weeks of your last radiation session.
- Your blood counts, liver and kidney function must be within acceptable ranges.
- You must be willing to use reliable birth control during treatment and for one year after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
This trial tests whether adding an immunotherapy drug called sintilimab to standard chemoradiotherapy (chemo and radiation) is better than chemoradiotherapy alone for a specific type of nasopharyngeal cancer that has spread to neck lymph nodes. Immunotherapy uses your own immune system to fight cancer, and the hope is that adding it before and after standard treatment can improve outcomes.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
This trial tests a combination of two chemotherapy drugs (called TC) given after surgery to remove a nasopharyngeal cancer that has come back locally. The goal is to see if this treatment helps prevent the cancer from returning again and is safe for patients.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.